|147.50||+1.20||+0.82%||Vol 1.53M||1Y Perf -15.76%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||-0.69 -0.47%|
|Target Price||212.33||Analyst Rating||Strong Buy 1.50|
|Potential %||43.95||Finscreener Ranking||★ 41.67|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 38.51|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★ 37.70|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||31.69||Earnings Rating||Buy|
|Market Cap||17.82B||Earnings Date||2nd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|10 Years||1 167.18%|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Aug 2022|
|Estimated EPS Next Report||-1.63|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||996.28K|
|Avg. Monthly Volume||820.17K|
|Avg. Quarterly Volume||808.89K|
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock closed at 147.5 per share at the end of the most recent trading day (a 0.82% change compared to the prior day closing price) with a volume of 1.53M shares and market capitalization of 17.82B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1453 people. Alnylam Pharmaceuticals Inc. CEO is John M. Maraganore.
The one-year performance of Alnylam Pharmaceuticals Inc. stock is -15.76%, while year-to-date (YTD) performance is -13.02%. ALNY stock has a five-year performance of 73.1%. Its 52-week range is between 117.58 and 212, which gives ALNY stock a 52-week price range ratio of 31.69%
Alnylam Pharmaceuticals Inc. currently has a PE ratio of -18.30, a price-to-book (PB) ratio of 41.29, a price-to-sale (PS) ratio of 18.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -26.70%, a ROC of -56.48% and a ROE of -134.53%. The company’s profit margin is -97.99%, its EBITDA margin is -74.20%, and its revenue ttm is $879.98 Million , which makes it $7.28 revenue per share.
Of the last four earnings reports from Alnylam Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.63 for the next earnings report. Alnylam Pharmaceuticals Inc.’s next earnings report date is 02nd Aug 2022.
The consensus rating of Wall Street analysts for Alnylam Pharmaceuticals Inc. is Strong Buy (1.5), with a target price of $212.33, which is +43.95% compared to the current price. The earnings rating for Alnylam Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alnylam Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alnylam Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.27, ATR14 : 6.06, CCI20 : 176.23, Chaikin Money Flow : 0.26, MACD : 2.27, Money Flow Index : 73.47, ROC : 10.07, RSI : 64.47, STOCH (14,3) : 97.08, STOCH RSI : 1.00, UO : 71.92, Williams %R : -2.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alnylam Pharmaceuticals Inc. in the last 12-months were: Akshay K. Vaishnaw (Option Excercise at a value of $682 542), Akshay K. Vaishnaw (Sold 13 423 shares of value $2 661 443 ), John M. Maraganore (Option Excercise at a value of $882 324), John M. Maraganore (Sold 67 957 shares of value $12 615 995 ), Laurie B. Keating (Option Excercise at a value of $1 488 270), Laurie B. Keating (Sold 16 812 shares of value $3 108 598 ), Steven M. Paul (Option Excercise at a value of $169 950), Steven M. Paul (Sold 15 000 shares of value $2 560 371 ), Tolga Tanguler (Option Excercise at a value of $0), Yvonne Greenstreet (Option Excercise at a value of $4 091 234), Yvonne Greenstreet (Sold 53 064 shares of value $10 559 736 ), Yvonne L Greenstreet (Option Excercise at a value of $4 091 234), Yvonne L Greenstreet (Sold 53 064 shares of value $10 559 736 )
Thu, 23 Jun 2022 10:45 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Zynerba Pharmaceuticals (ZYNE)- TipRanks. All rights reserved.
Wed, 15 Jun 2022 12:25 GMT Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Amgen (AMGN)- TipRanks. All rights reserved.
Wed, 15 Jun 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Tenaya Therapeutics (TNYA)- TipRanks. All rights reserved.
Tue, 24 May 2022 12:26 GMT Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Cytokinetics (CYTK)- TipRanks. All rights reserved.
Fri, 29 Apr 2022 11:15 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) and Sanofi (OtherSNYNF)- TipRanks. All rights reserved.
Mon, 04 Apr 2022 15:55 GMT Alnylam Pharma (ALNY) Gets a Buy Rating from Needham- TipRanks. All rights reserved.
Sun, 13 Feb 2022 14:46 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AstraZeneca (AZN) and Dexcom (DXCM)- TipRanks. All rights reserved.
Fri, 11 Feb 2022 12:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Cigna (CI) and SCYNEXIS (SCYX)- TipRanks. All rights reserved.
Thu, 10 Feb 2022 18:55 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB)- TipRanks. All rights reserved.
Mon, 24 Jan 2022 13:25 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Merck & Company (MRK)- TipRanks. All rights reserved.
Mon, 24 Jan 2022 11:15 GMT Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Reviva Pharmaceuticals Holdings (RVPH)- TipRanks. All rights reserved.
Tue, 11 Jan 2022 14:46 GMT Alnylam Pharma (ALNY) Gets a Hold Rating from BMO Capital- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.